Clinical Use of κ Free Light Chains Index as a Screening Test for Multiple Sclerosis.
CSF
OCB
biomarker
free light chain
multiple sclerosis
κFLC
κFLC index
Journal
Laboratory medicine
ISSN: 1943-7730
Titre abrégé: Lab Med
Pays: England
ID NLM: 0250641
Informations de publication
Date de publication:
08 Jul 2020
08 Jul 2020
Historique:
pubmed:
17
1
2020
medline:
21
4
2021
entrez:
17
1
2020
Statut:
ppublish
Résumé
To assess the usefulness of the κ free light chain index (κFLCi) as a screening test to identify patients with suspected MS. The study included 56 patients with a request to test for oligoclonal bands (OCBs). OCBs were detected by isoelectric focusing, followed by immunofixation. Cerebrospinal fluid (CSF) and serum κFLC were measured by a turbidimetric assay. Also, the κFLC index (κFLCi) was calculated. CSF κFLC levels and κFLCi were significantly higher in patients with multiple sclerosis (MS) than in patients with other neurological diseases (NDs; P < .001 and P < .001, respectively). At the cutoff value of 2.9, the κFLCi detected MS with sensitivity of 97% and specificity of 65%. Overall, 92% patients with κFLCi of 2.9 or greater and who had tested positive for OCBs were diagnosed as having MS. Our findings support the use of κFLCi as a screening test when MS is suspected, followed by OCB detection as a confirmatory test for the diagnosis of MS.
Identifiants
pubmed: 31943078
pii: 5706677
doi: 10.1093/labmed/lmz073
doi:
Substances chimiques
Biomarkers
0
Immunoglobulin Light Chains
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
402-407Informations de copyright
© American Society for Clinical Pathology 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.